Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)
  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling.
 
DeviceOrganOx metra System
Generic NameNormothermic machine perfusion system for the preservation of donor livers prior to transplantation
ApplicantOrganOx Limited
Oxford Science Park, Magdalen Centre, Robert Robinson Avenue
Oxford OX4 4
PMA NumberP200035
Date Received07/15/2020
Decision Date12/09/2021
Product Code QQK 
Docket Number 21M-1317
Notice Date 12/17/2021
Advisory Committee Gastroenterology/Urology
Clinical TrialsNCT02775162
Expedited Review Granted? No
Combination ProductNo
Approval Order Statement  
Approval for the OrganOx metra System. The device is approved for the following indication: The OrganOx metra® is a transportable device intended to be used to sustain donor livers destined for transplantation in a functioning state for a total preservation time of up to 12 hours.The OrganOx metra® device is suitable for liver grafts from donors after brain death (DBD), or liver grafts from donors after circulatory death (DCD) <=40 years old, with <=20 mins of functional warm ischemic time (time from donor systolic blood pressure <50 mmHg), and macrosteatosis <=15%, in a near-physiologic, normothermic and functioning state intended for a potential transplant recipient.
Approval OrderApproval Order
SummarySummary of Safety and Effectiveness
LabelingLabeling
Labeling Part 2
Post-Approval StudyShow Report Schedule and Study Progress
Supplements:  S001 S002 S003 S005 S006 S007 S008 S009 S010 S011 S012 
S013 S014 
-
-